Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

Sonja Zweegman, Saad Z. Usmani, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep M. Marti, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Angelo Maiolino, Mai Ngo, Lorena Lopez-Masi, Fredrik Borgsten, Melissa Rowe, Robin L. Carson, Thierry Facon

Open source

DOI: 10.1038/s41375-026-03111-0
Published: 2026-08-18
Container: Leukemia
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41375-026-03111-0,
  title = {Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS},
  author = {Sonja Zweegman and Saad Z. Usmani and Vania Hungria and Nizar J. Bahlis and Christopher P. Venner and Marc Braunstein and Ludek Pour and Josep M. Marti and Supratik Basu and Yael C. Cohen and Morio Matsumoto and Kenshi Suzuki and Cyrille Hulin and Sebastian Grosicki and Wojciech Legiec and Angelo Maiolino and Mai Ngo and Lorena Lopez-Masi and Fredrik Borgsten and Melissa Rowe and Robin L. Carson and Thierry Facon},
  year = {2026},
  journal = {Leukemia},
  doi = {10.1038/s41375-026-03111-0},
  url = {https://doi.org/10.1038/s41375-026-03111-0}
}

RIS

TY  - JOUR
TI  - Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS
AU  - Sonja Zweegman
AU  - Saad Z. Usmani
AU  - Vania Hungria
AU  - Nizar J. Bahlis
AU  - Christopher P. Venner
AU  - Marc Braunstein
AU  - Ludek Pour
AU  - Josep M. Marti
AU  - Supratik Basu
AU  - Yael C. Cohen
AU  - Morio Matsumoto
AU  - Kenshi Suzuki
AU  - Cyrille Hulin
AU  - Sebastian Grosicki
AU  - Wojciech Legiec
AU  - Angelo Maiolino
AU  - Mai Ngo
AU  - Lorena Lopez-Masi
AU  - Fredrik Borgsten
AU  - Melissa Rowe
AU  - Robin L. Carson
AU  - Thierry Facon
PY  - 2026
JO  - Leukemia
DO  - 10.1038/s41375-026-03111-0
UR  - https://doi.org/10.1038/s41375-026-03111-0
ER  -

APA

Zweegman, S., Usmani, S. Z., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M., Pour, L., Marti, J. M., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Maiolino, A., Ngo, M., Lopez-Masi, L., Borgsten, F., Rowe, M., Carson, R. L., & Facon, T. (2026). Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS. Leukemia. https://doi.org/10.1038/s41375-026-03111-0

Source records

crossref · retrieved 2026-09-25T08:52:39.947Z